These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 27271184)

  • 1. CYP2C8 and SLCO1B1 Variants and Therapeutic Response to Thiazolidinediones in Patients With Type 2 Diabetes.
    Dawed AY; Donnelly L; Tavendale R; Carr F; Leese G; Palmer CN; Pearson ER; Zhou K
    Diabetes Care; 2016 Nov; 39(11):1902-1908. PubMed ID: 27271184
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of SLCO1B1 and CYP2C8 gene polymorphisms on rosiglitazone pharmacokinetics in healthy volunteers.
    Aquilante CL; Bushman LR; Knutsen SD; Burt LE; Rome LC; Kosmiski LA
    Hum Genomics; 2008 Sep; 3(1):7-16. PubMed ID: 19129086
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Polymorphic organic anion transporting polypeptide 1B1 is a major determinant of repaglinide pharmacokinetics.
    Niemi M; Backman JT; Kajosaari LI; Leathart JB; Neuvonen M; Daly AK; Eichelbaum M; Kivistö KT; Neuvonen PJ
    Clin Pharmacol Ther; 2005 Jun; 77(6):468-78. PubMed ID: 15961978
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multicenter retrospective assessment of thiazolidinedione monotherapy and combination therapy in patients with type 2 diabetes: comparative subgroup analyses of glycemic control and blood lipid levels.
    Olansky L; Marchetti A; Lau H
    Clin Ther; 2003; 25 Suppl B():B64-80. PubMed ID: 14553867
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of CYP2C8 and SLCO1B1 Genetic Polymorphisms on Repaglinide Pharmacokinetics: A Systematic Review and Meta-Analysis.
    Zhou S; Xiang Q; Mu G; Ma L; Chen S; Xie Q; Zhang Z; Cui Y
    Curr Drug Metab; 2019; 20(4):266-274. PubMed ID: 30636597
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A meta-analysis comparing the effect of thiazolidinediones on cardiovascular risk factors.
    Chiquette E; Ramirez G; Defronzo R
    Arch Intern Med; 2004 Oct; 164(19):2097-104. PubMed ID: 15505122
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of functional CYP2C8,CYP2C9,CYP3A5,and ABCB1 genetic variants on the pharmacokinetics of insulin sensitizer pioglitazone in Chinese Han individuals.
    Yin SJ; Qi HM; Wang X; Zhang P; Lu Y; Wei MJ; Li P; Qi GZ; Lou YQ; Lu C; Zhang GL
    Pharmacogenet Genomics; 2017 Apr; 27(4):125-134. PubMed ID: 28099407
    [TBL] [Abstract][Full Text] [Related]  

  • 8. No significant effect of SLCO1B1 polymorphism on the pharmacokinetics of rosiglitazone and pioglitazone.
    Kalliokoski A; Neuvonen M; Neuvonen PJ; Niemi M
    Br J Clin Pharmacol; 2008 Jan; 65(1):78-86. PubMed ID: 17635496
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A meta-analysis on treatment effects of thiazolidinediones for type 2 diabetes mellitus in Asian populations.
    Louisa M; Takeuchi M; Takeuchi M; Nafrialdi ; Setiabudy R
    Acta Med Indones; 2011 Jan; 43(1):39-52. PubMed ID: 21339545
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Application of in vitro-in vivo extrapolation (IVIVE) and physiologically based pharmacokinetic (PBPK) modelling to investigate the impact of the CYP2C8 polymorphism on rosiglitazone exposure.
    Yeo KR; Kenny JR; Rostami-Hodjegan A
    Eur J Clin Pharmacol; 2013 Jun; 69(6):1311-20. PubMed ID: 23307233
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genome-Wide Meta-analysis Identifies Genetic Variants Associated With Glycemic Response to Sulfonylureas.
    Dawed AY; Yee SW; Zhou K; van Leeuwen N; Zhang Y; Siddiqui MK; Etheridge A; Innocenti F; Xu F; Li JH; Beulens JW; van der Heijden AA; Slieker RC; Chang YC; Mercader JM; Kaur V; Witte JS; Lee MTM; Kamatani Y; Momozawa Y; Kubo M; Palmer CNA; Florez JC; Hedderson MM; 't Hart LM; Giacomini KM; Pearson ER; ;
    Diabetes Care; 2021 Dec; 44(12):2673-2682. PubMed ID: 34607834
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness and side effects of thiazolidinediones for type 2 diabetes: real-life experience from a tertiary hospital.
    Hussein Z; Wentworth JM; Nankervis AJ; Proietto J; Colman PG
    Med J Aust; 2004 Nov; 181(10):536-9. PubMed ID: 15540964
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A variant of GRK5 is associated with the therapeutic efficacy of repaglinide in Chinese Han patients with type 2 diabetes mellitus.
    Shang Z; Han F; Zhou X; Bao Z; Zhu J; Wang T; Lu Q; Du L; Li W; Lv D; Yin X
    Drug Dev Res; 2018 May; 79(3):129-135. PubMed ID: 29663513
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Saxagliptin added to a thiazolidinedione improves glycemic control in patients with type 2 diabetes and inadequate control on thiazolidinedione alone.
    Hollander P; Li J; Allen E; Chen R;
    J Clin Endocrinol Metab; 2009 Dec; 94(12):4810-9. PubMed ID: 19864452
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The pharmacogenetics of type 2 diabetes: a systematic review.
    Maruthur NM; Gribble MO; Bennett WL; Bolen S; Wilson LM; Balakrishnan P; Sahu A; Bass E; Kao WH; Clark JM
    Diabetes Care; 2014; 37(3):876-86. PubMed ID: 24558078
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of genetic polymorphisms in cytochrome p450 (CYP) 2C9 and CYP2C8 on the pharmacokinetics of oral antidiabetic drugs: clinical relevance.
    Kirchheiner J; Roots I; Goldammer M; Rosenkranz B; Brockmöller J
    Clin Pharmacokinet; 2005; 44(12):1209-25. PubMed ID: 16372821
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of genetic variants in CYP2C8, LPIN1, PPARGC1A and PPARγ on the trough steady-state plasma concentrations of rosiglitazone and on glycosylated haemoglobin A1c in type 2 diabetes.
    Stage TB; Christensen MM; Feddersen S; Beck-Nielsen H; Brøsen K
    Pharmacogenet Genomics; 2013 Apr; 23(4):219-27. PubMed ID: 23426382
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of pharmacogenomic SLCO1B1 assay for prediction of neuromuscular pain in type 2 diabetes mellitus and cardiovascular patients: preliminary results.
    Licito A; Marotta G; Battaglia M; Benincasa G; Mentone L; Grillo MR; De Lucia V; Leonardi G; Bignucolo A; Comello F; Di Francia R; De Lucia D
    Eur Rev Med Pharmacol Sci; 2020 Jan; 24(1):469-477. PubMed ID: 31957862
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of 1 year of treatment with pioglitazone or rosiglitazone added to glimepiride on lipoprotein (a) and homocysteine concentrations in patients with type 2 diabetes mellitus and metabolic syndrome: a multicenter, randomized, double-blind, controlled clinical trial.
    Derosa G; Cicero AF; D'Angelo A; Gaddi A; Ciccarelli L; Piccinni MN; Salvadeo SA; Pricolo F; Ferrari I; Gravina A; Ragonesi PD
    Clin Ther; 2006 May; 28(5):679-88. PubMed ID: 16861090
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Physiologically Based Pharmacokinetic Models for Prediction of Complex CYP2C8 and OATP1B1 (SLCO1B1) Drug-Drug-Gene Interactions: A Modeling Network of Gemfibrozil, Repaglinide, Pioglitazone, Rifampicin, Clarithromycin and Itraconazole.
    Türk D; Hanke N; Wolf S; Frechen S; Eissing T; Wendl T; Schwab M; Lehr T
    Clin Pharmacokinet; 2019 Dec; 58(12):1595-1607. PubMed ID: 31129789
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.